China's top COVID-19 vaccine candidate showed weak results among older Phase II test subjects


China's CanSino Biologics reported preliminary results of its Phase II COVID-19 vaccine trial Monday, and there was promising news. But it was overshadowed by the results of the Oxford University-AstraZeneca vaccine, also published Monday in the journal The Lancet. Both vaccines, among the top contenders in the global race for a coronavirus immunization drug, produced strong immune responses with only minor side effects, but older trial participants showed significantly weaker responses in the CanSino trial, suggesting two doses may be needed.
CanSino's vaccine appears "pretty weak compared to other vaccine candidates (to the extent that comparisons are possible)," said Prof. John Moore at Weill Cornell Medical School. However, comparing the immune response among different vaccines is tricky, he added, "like judging a beautiful baby photo contest when every mom uses a different Instagram filter."
The Oxford-AstraZeneca vaccine and CanSino's candidate both use genetically deactivated adenoviruses that mimic the new coronavirus and stimulate an immune response. But while Oxford's vaccine uses an adenovirus found in chimps, CanSino relies on an adenovirus that causes the common cold in humans. Monday's CanSino study "revealed that people who had previously been exposed to the cold virus showed weaker immune responses to the coronavirus vaccine — presumably because their immune systems zeroed in on the familiar component of the vaccine, the weakened cold virus, rather than SARS-CoV-2," Politico explains.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
CanSino and Oxford-AstraZeneca already have large-scale Phase III trials underway to judge their vaccines' efficacy, and CanSino's is the only COVID-19 vaccine approved for use, though approval is limited to China's military. Monday's reports show that "each of these vaccines is worth taking all the way through to a Phase III study," Dr. Peter Jay Hotez, a vaccine researcher at the Baylor College of Medicine, tells The New York Times. "That is it. All it means is 'worth pursuing.'"
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Sloth fever shows no signs of slowing down
The explainer The vector-borne illness is expanding its range
-
'With every technological advance, there are risks'
Instant Opinion Opinion, comment and editorials of the day
-
5 of the best platonic TV friendships
the week recommends Maintaining boundaries has proven tricky for all but the most committed of buddies on the small screen
-
New York court tosses Trump's $500M fraud fine
Speed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in Intel
Speed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year